Studies were carried out in humans and in rhesus monkeys to determine the role of the kidneys in the metabolism of circulating mevalonic acid (MVA). Following intravenous infusion of [14C]MVA and [3H]cholesterol, there was a rapid appearance of [14C]squalene in the kidneys that exhibited a significantly longer half-life than plasma or hepatic squalene. In man and in rhesus monkeys there was a rapid equilibration between newly synthesized cholesterol from MVA and exogenously administered cholesterol in all tissues except the kidneys, where the specific activity ratio of newly synthesized to exogenous cholesterol was significantly higher. Estimates of the quantitative metabolism of intravenously infused radiolabeled MVA in the monkey demonstrated that 23% was excreted in the urine, 67% metabolized to cholesterol (58% in nonrenal tissues and 9% in the kidneys), and 10% catabolized to CO2 and nonsteroid products. Measurements of MVA metabolism in anephric and uninephric patients demonstrate that, in the absence of renal uptake of MVA, exogenous and newly synthesized cholesterol achieve almost instantaneous equilibrium in the plasma; whereas in control subjects with normal renal function, this equilibration required at least 21 d for the two cholesterol decay curves to become parallel. These results suggest that the kidneys are solely responsible for the observed disequilibrium between newly synthesized and exogenous cholesterol; we suggest that this was due to the delayed release of newly synthesized cholesterol from the kidneys into the plasma compartment following intravenous infusion with radiolabeled MVA. The data document the importance of the kidneys in the metabolism of circulating MVA. However, calculation of the quantitative significance of this pathway in relation to whole body MVA metabolism indicates that renal metabolism of MVA accounts for approximately 0.1% of daily MVA turnover, and that alterations in this pathway due to any form of renal pathology would not result in significant changes in hepatic or whole body sterol synthesis rates. We urge caution in the use of radiolabeled MVA in long-term kinetic studies of sterol metabolism because our data show that the plasma compartment of MVA is not necessarily in isotopic equilibrium with tissue MVA.
D J McNamara, E H Ahrens Jr, T S Parker, K Morrissey
Title and authors | Publication | Year |
---|---|---|
Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC–MS/MS method
AV Rodrigues, JL Maggs, SJ McWilliam, M Pirmohamed, M Coen, ID Wilson, BK Park, DJ Antoine |
Bioanalysis | 2014 |
Pravastatin improves renal ischemia–reperfusion injury by inhibiting the mevalonate pathway
S Sharyo, N Yokota-Ikeda, M Mori, K Kumagai, K Uchida, K Ito, MJ Burne-Taney, H Rabb, M Ikeda |
Kidney International | 2008 |
The influence of sleep and sleep loss upon food intake and metabolism
CA Crispim, I Zalcman, M Dáttilo, HG Padilha, B Edwards, J Waterhouse, S Tufik, MT de Mello |
Nutrition Research Reviews | 2007 |
Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans
BH Prinsen, JA Romijn, PH Bisschop, MM de Barse, PH Barrett, M Ackermans, R Berger, TJ Rabelink, MG de der Velden |
Journal of lipid research | 2003 |
Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions
Pfohl, Naoumova, Kim, Thompson |
European Journal of Clinical Investigation | 1998 |
The Mevalonate Pathway and Renal Diseases: Experimental and Clinical Implications
A Scoppola, P Galiano |
The International Journal of Artificial Organs | 1998 |
Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans
T Yoshida, A Honda, J Shoda, M Abei, Y Matsuzaki, N Tanaka, H Miyazaki, T Osuga |
Lipids | 1997 |
Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect
M Pfohl, RP Naoumova, C Neuwirth, A Sussekov, J Smykowski, NB Rendell, GW Taylor, FJ Seif, GR Thompson |
Atherosclerosis | 1997 |
Plasma mevalonate concentrations in uremic patients
A Scoppola, PD Paolis, G Menzinger, A Lala, SD Giulio |
Kidney International | 1997 |
1,25-Dihydroxyvitamin D3-induced HL-60 macrophages: regulation of cholesterol and LDL metabolism
ZE Jouni, JJ Winzerling, DJ McNamara |
Atherosclerosis | 1995 |
Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans
PJ Boyle, A Avogaro, L Smith, DM Bier, AS Pappu, DR Illingworth, PE Cryer |
American journal of physiology. Endocrinology and metabolism | 1992 |
Whole body and hepatic cholesterol synthesis rates in the guinea-pig: effect of dietary fat quality
ML Fernandez, NY Yount, DJ McNamara |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1990 |
High-density lipoprotein cholesteryl ester and protein catabolism in hypercholesterolemic rats induced by copper deficiency
TP Carr, KY Lei |
Metabolism | 1990 |
The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat
TA Golper, KR Feingold, MH Fulford, MD Siperstein |
Journal of lipid research | 1990 |
Measurement of mevalonate in human plasma and urine by multiple selected ion monitoring
MD Puppo, G Cighetti, MG Kienle, LD Angelis |
Biological Mass Spectrometry | 1989 |
Cholesterol homeostasis in guinea pigs fed saturated and polyunsaturated fat diets
JB Ibrahim, DJ McNamara |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1988 |
Expression of specific high capacity mevalonate transport in a Chinese hamster cell variant
J Faust, M Krieger |
The Journal of biological chemistry | 1987 |